Efficacy of leptin therapy in the different forms of human lipodystrophy.
about
New advances in the treatment of generalized lipodystrophy: role of metreleptinLeptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individualsPathogenesis of the metabolic syndrome: insights from monogenic disordersLeptin applications in 2015: what have we learned about leptin and obesity?The effects of diet composition on body fat and hepatic steatosis in an animal (Peromyscus californicus) model of the metabolic syndrome.Rare adipose disorders (RADs) masquerading as obesity.Leptin revisited: its mechanism of action and potential for treating diabetes.The role of leptin in glucose homeostasis.The clinical approach to the detection of lipodystrophy - an AACE consensus statementBone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.Comparative endocrinology of leptin: assessing function in a phylogenetic contextLipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglyceridesLocus of control and obesity.Metreleptin: first global approval.Lipodystrophy syndromesCardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment.Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons.Lipodystrophy: pathophysiology and advances in treatmentGenetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know.Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experiencePartial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.Barraquer-Simons syndrome: a rare form of acquired lipodystrophy.Leptin in relation to the lipodystrophy-associated metabolic syndromeLeptin as a modulator of neuroendocrine function in humansPregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction.Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.Is there a human model for the 'metabolic syndrome' with a defined aetiology?A new look at the genetic and environmental coherence of metabolic syndrome componentsPharmacotherapy for childhood obesity: present and future prospects.Lymphoma in acquired generalized lipodystrophy.What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.Leptin therapy, insulin sensitivity, and glucose homeostasis.Leptin in pediatrics: A hormone from adipocyte that wheels several functions in children.Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.Onset of leptin resistance shows temporal differences related to dose or pulsed treatmentImmunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophyNovel forms of lipodystrophy: why should we care?
P2860
Q26781946-0409583C-56AD-43C5-BE7B-87D52CD8F160Q26859118-866C4509-FA7A-431F-A225-A85C1EF8F4E1Q27024024-8A4F3143-D8E5-4A9F-80D3-EE98E6468D3DQ28087233-79092F20-8712-443B-9BC7-8822A5CF3859Q30431218-B39DAF5E-6210-4E1D-95C8-0A1147E8E17AQ33567310-AF920B0B-984D-4F71-B054-06B6E87A1FF2Q33602487-0C8DA9FC-568F-451D-85BD-8AFD5BF24B9FQ33609782-BD171CD1-4B01-45E7-8536-C05FFE548084Q33939518-23BFCDB0-9AE8-41A9-B995-001D3916B861Q33999013-63777A94-4576-473A-A60C-079A0FCA559AQ34028808-224D3B4B-85C6-4DEB-8D38-8283624F45BEQ34131027-810E5776-FCB4-43DA-BBA9-3BBD631502DFQ34299762-2B9A0D81-AC99-4C54-A7CF-CFFA571374A9Q34348966-FC3B8544-647C-4E54-B0CD-99864518007BQ34597209-87B367F6-3199-4588-8E3D-CDA02CA3254FQ34954748-854847EF-AAC9-44D5-9460-733CF60C4685Q34973920-72DFE9C6-0B7C-4B5A-B6B6-CE07CF4F5FBFQ35148915-39F95CF7-8491-4D34-99CF-7C8145F81E4DQ35178218-3ADBA75A-871B-44A5-B3EF-EF4E266DB48AQ35480563-7F2E0A88-3002-4687-8BA0-00A2B36EE535Q35547148-FF0C6A85-BE7C-419D-AB8F-FDD1EACDB500Q35578335-2F061468-5671-4645-B7F6-868AEE95B0FBQ35869668-667BD070-6614-4B5F-9145-30D8143AA68BQ35961396-48E6D38F-4A7D-4CF8-8C8B-20F7610D2BE2Q36049195-FC65BAF6-5FC0-420F-99E7-2BCC83EF9F97Q36053489-ACB1F580-02A5-40AE-9B70-794574CB46BAQ36314746-D12308F1-4B8F-4B37-89E0-FF5558490BCFQ36400947-FE7C9EA6-B6F3-47A6-81BB-4E7B3D465195Q36404679-8A2707FA-6AF4-463B-949A-BF7FBEF3530EQ36431050-0F3D248D-0EE8-475C-9F0A-A62DE7FCCF18Q36468087-A07E57A0-7320-419E-8F30-6C3C106199DFQ36584738-C5E40274-8E15-43CB-AD43-57BAC9EB4860Q36616784-417ED6AF-21B6-49C5-9A5E-711A6153B153Q36661713-5E649869-A71D-431E-AAB6-F1A523C342B5Q36700877-CFF4E124-4D10-463E-9178-241C7063AC9DQ36700895-DDD2FD45-DFED-4B71-968B-960DB3952283Q36753809-8DC70D1E-B77C-4647-82B6-219D6C06A610Q36815153-7BBA9290-A8B8-49E3-B876-060EB1116A67Q36923891-644DE338-6BB8-44D9-A9A5-3C8D18C7188EQ37022579-58D99A86-6CDE-4A7C-8870-8FA57620585D
P2860
Efficacy of leptin therapy in the different forms of human lipodystrophy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@en
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@nl
type
label
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@en
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@nl
prefLabel
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@en
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@nl
P2093
P1433
P1476
Efficacy of leptin therapy in the different forms of human lipodystrophy.
@en
P2093
P2860
P2888
P356
10.1007/S00125-009-1502-9
P577
2009-09-02T00:00:00Z